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Abstract
Summary Changes in bone turnover markers with weekly
56.5 μg teriparatide injections for 24 weeks were investigated
in women with osteoporosis. Changes in bone turnover
markers 24 h after each injection of teriparatide were constant.
During the 24 week period, bone formation markers increased
and baseline bone resorption marker levels were maintained.
Introduction This study aimed to clarify the changes in bone
turnover markers during 24 weeks of once-weekly teriparatide
injections in postmenopausal women with osteoporosis.
Methods The 24 h changes in pharmacokinetics (PK), calcium
metabolism, and bone turnover markers (serum osteocalcin,
procollagen type I N-terminal propeptide (P1NP), urinary
cross-linked N-telopeptide of type I collagen (NTX),
deoxypiridinoline (DPD)) after each injection of 56.5 μg
teriparatide at the data collectionweeks (0, 4, 12, and 24weeks)
were investigated. The changes were evaluated by comparison
with the data at 0 h in each data collection week.
Results Similar 24 h changes in each parameter after injection
of teriparatide were observed in each data collection week.
Serum calcium increased transiently, and intact PTH de-
creased 4–8 h after injection; serum calcium subsequently
returned to baseline levels. Calcium and intact PTH levels
decreased for 24 weeks. Although serum osteocalcin de-
creased at 24 h, it was significantly increased at 4 weeks.
P1NP decreased transiently and then increased significantly
at 24 h. P1NP was significantly increased at 4 weeks. Urinary
NTX and DPD were significantly increased transiently and
then decreased at 24 h. The urinary DPD level decreased
significantly at 4 weeks.
Conclusions Twenty-four hour changes in PK, calcium me-
tabolism, and bone turnover markers showed the same direc-
tion and level after once-weekly teriparatide injections for
24 weeks, with no attenuation of the effect over time. After
24 weeks, the bone formation marker, serum osteocalcin,
increased significantly, but the serum P1NP, did not. Bone
resorption markers decreased or remained the same.
Keywords Bone formation . Bone resorption . Calcium
metabolism . Human . Teriparatide
Introduction
Human parathyroid hormone (PTH) 1–34 (teriparatide) has
been widely used in Japan for the treatment of osteoporosis
with a high risk of fracture as a 20 μg daily regimen [1–3] and
a 56.5 μg once-weekly regimen [4]. It has been reported that,
with intermittent use, teriparatide has an anabolic action on the
bone. The effects on bone turnover markers have been shown
to differ between the 20 μg daily regimen and the 56.5 μg
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once-weekly regimen [4–6]. Although daily injection in-
creases bone formation and bone resorption, weekly injection
increases bone formation moderately and decreases or main-
tains bone resorption. However, the effects on bone mineral
density and reduction of vertebral fractures are similar.
We have previously reported changes in calcium metabo-
lism and bone turnover markers following single injections of
teriparatide (28.2 and 56.5 μg) in healthy elderly women [7].
It has been observed that a single injection of teriparatide
causes an immediate, transient increase in bone resorption
and a decrease in bone formation, followed by increased
bone formation and decreased bone resorption for at least
1 week. These findings provide substantial proof of the
effect of a once-weekly regimen of teriparatide on bone
turnover. However, both repetition of the 24 h change with
each injection and changes in levels of each parameter over
a long period have not been evaluated in postmenopausal
women with osteoporosis.
In this study, the profile of changes (0 to 24 h and 0 to
24 weeks) in pharmacokinetics (PK), calcium metabolism,
and bone turnover markers during weekly injection of
56.5 μg of teriparatide for 24 weeks in postmenopausal women
with osteoporosis was investigated.
Subjects and methods
Study subjects
This study was conducted at four institutes in Japan. The
subjects were 28 postmenopausal Japanese women with oste-
oporosis, ranging in age from 60 to 79 years. The inclusion
criteria included postmenopausal women without a concomi-
tant allergic diathesis, calcium abnormalities, and drug use
that may affect bone metabolism within 8 weeks prior to the
study. Subjects who had taken bisphosphonates within the
past 52 weeks were excluded. Women who had secondary
osteoporosis, osteopenia due to a bone metabolism disorder,
body weight lower than 40 kg, red blood cell number less
than 300×104/μL or hemoglobin less than 9.5 g/dL, se-
rum calcium greater than 11 mg/dL, severe renal, liver, or
heart dysfunction, a risk of osteosarcoma, or higher alka-
line phosphatase levels were excluded. Osteoporosis was
diagnosed by the following criteria: (1) bone mineral
density (BMD) at the lumbar spine or femoral neck in
less than 80 % of the young adult mean (YAM) in the
Japanese population and the presence of a fragility fracture
and (2) BMD at the lumbar spine or femoral neck in less
than 70 % of YAM. Furthermore, as additive criteria for
osteoporosis, the following itemswere included: age ≥65 years,
previous fragility fracture at older than 50 years of age, or ≥1
pre-existing vertebral fracture.
Treatment protocol
Subjects were given weekly subcutaneous injections of
56.5 μg teriparatide for 24 weeks. Teriparatide was supplied
by Asahi Kasei Pharma Corporation (Tokyo, Japan). All sub-
jects were receiving daily calcium (610 mg), vitamin D
(400 IU), and magnesium (30 mg) supplements.
Data collection
Blood and urine samples were collected in weeks 0, 4, 12, and
24. In the data collection week, 0 h examinations were
performed at 0800. Teriparatide was administered immediate-
ly after 0 h collection of blood and urine samples. Blood
samples for PK were collected at 0, 0.5, 1, 2, 4, 6, 8, 12, and
24 h after the injection. Serum and urine samples for measure-
ments of bone turnover markers were collected at 0, 2, 4, 6, 8,
12, and 24 h after the injection. BMD at the lumbar spine was
measured at 0 and 24 weeks.
Outcome measures
PK and changes in calcium metabolism, bone turnover markers,
and BMD were measured. Plasma teriparatide concentrations
were measured at Sekisui Medical Co., Ltd (Tokyo, Japan) using
a rat PTH immunoradiometric assay kit (IRMA; Immutopics Inc.,
San Clemente, CA, USA) with a range of 10 to 1,000 pg/mL.
Serum calcium (Ca) was measured at Mitsubishi Chemical
Medience Co (Tokyo, Japan). Serum intact PTH levels were
measured by an electrochemiluminescence immunoassay (Roche
Diagnostics K.K., Tokyo, Japan). 25-hydroxy vitamin D
(25(OH)D) was measured by a competitive protein-binding assay
(Mitsubishi Chemical Medience Co). Serum levels of the bone
turnover markers, osteocalcin and procollagen type I N-terminal
propeptide (P1NP) (both bone formation markers), were mea-
sured by BGP-IRMA (Mitsubishi Chemical Medience Co) and
bone radioimmunoassay (Orion Diagnostic, Espoo, Finland), re-
spectively (the coefficients of variation were previously reported
[4]). Urinary cross-linked N-telopeptide of type I collagen (NTX;
Osteomark, Inverness Medical Innovations Inc, Waltham, MA,
USA) was measured by ELISA, and urinary deoxypiridinoline
(DPD)wasmeasured byMitsubishi ChemicalMedienceCo; both
are bone resorption markers. The inter-assay coefficients of vari-
ation were described in a previous report [7]. Samples were
measured at each sampling time. Lumbar BMD was measured
usingDXA/QDR (Hologic, Bedford,MA,USA). Adverse events
(AEs) were investigated by the physicians and classified using the
system organ class from MedDRAversion 12.0.
Statistical analysis
The concentrations of teriparatide, calcium metabolism,
and bone turnover markers are expressed as means±SE.
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In the 24 h change analysis, calcium metabolism and bone
turnover markers were compared to the 0 h value (paired t
test). The bone turnover markers and lumbar BMD are
expressed as the mean percent changes from corresponding
week 0 values. The changes from baseline were evaluated
using paired t test.
Ethical considerations
The protocol of the present study was approved by the Insti-
tutional Review Boards at each participating institution, and
the study was conducted in compliance with the Declaration
of Helsinki and Good Clinical Practice (GCP). Written,
informed consent was obtained from all participants prior to
their participation in the study.
Results
Subjects
Twenty-eight subjects with osteoporosis were enrolled in this
study. One subject was withdrawn from the study at the first
week of injection at the subject's request. The subjects' base-
line characteristics are shown in Table 1. The serum 25(OH)D
level was only measured at 0 weeks. One subject with a
vitamin D deficiency at baseline was not included.
Pharmacokinetics
The 24 h changes in plasma teriparatide acetate concen-
trations were nearly equal in each data collection week
(Fig. 1). No major difference was found in peak concentra-
tions at 30 min among 0, 4, 12, and 24 weeks. The distribu-
tions of mean values of PK parameters in each sampling week
were as follows: Cmax 495.9–653.9 pg/mL, AUClast 53.0–
70.5 ng·min/mL, AUCinf 55.5–74.1 ng·min/mL, Tmax 34.4–
41.1 min, and T1/2 57.4–123.4 min.
Changes in calcium metabolism
In each data collection week, the corrected serumCa increased
to a peak concentration (9.7–9.8 mg/dL) at 6 h and de-
creased to the baseline level at 12–24 h (Fig. 2a). During
the 24 week dosage period, the serum corrected Ca level
decreased significantly at 4 and 24 weeks (Fig. 2b). Serum
intact PTH decreased to its minimum concentration (25.6–
28.3 pg/mL) at 2 or 6 h and maintained a value lower than
the 0 h level at 24 h (Fig. 2c). During the dosage period of
24 weeks, the intact PTH level decreased significantly at
12 and 24 weeks (Fig. 2d).
Twenty-four hour changes in bone turnover markers after each
injection
The 24 h percent changes in bone turnover markers after each
teriparatide injection at each data collection week are shown in
Fig. 3. The serum osteocalcin level decreased to its minimum
value (−9.8 to −17.5 %) at 6, 8, or 24 h (Fig. 3a). The levels at
24 h were mostly significantly lower than at 0 h. The serum
P1NP decreased to its minimum value (−15.1 to −22.3 %) at
6 h and then increased significantly to about 5% (4.9 to 8.6%)
at 24 h after the teriparatide injection (Fig. 3b). The urinary
NTX increased to its maximum value (41.2 to 67.4 %) at 4 or
6 h and then decreased (Fig. 3c). The DPD increased to its
maximum value (29.5 to 31.6 %) at 2 or 4 h and then
decreased significantly (Fig. 3d). The profiles of the 24 h
changes in each bone turnover marker were almost the same
in each collection week.






Lumbar BMD (g/cm2) 0.668±0.076
Corrected serum Ca (mg/dL) 9.7±0.3
Serum P (mg/dL) 3.6±0.5
Serum intact PTH (pg/mL) 37.2±11.6
Serum 25(OH)D (ng/mL) 29.7±7.5
Serum osteocalcin (ng/mL) 7.9±3.3
Serum P1NP (ng/mL) 49.5±23.3
Urinary DPD (pmol/μmol · Cr) 5.0±2.2
Urinary NTX (nmol/mmol · Cr) 46.9±21.5
Fig. 1 Mean change over 24 h of the plasma concentration of teriparatide
acetate at 0 weeks (black circle), 4 weeks (white circle), 12 weeks (black
triangle), and 24 weeks (white triangle). Data are plotted as means (±SE)
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Changes in bone turnover marker levels over 24 weeks
Percent changes from baseline for 24 weeks were calculated
for serum osteocalcin and P1NP and urinary NTX and DPD.
The serum osteocalcin levels before each teriparatide injection
were significantly increased by 26.8 % at 4 weeks, and the
levels were maintained for 24 weeks (Fig. 4a). The serum
































Fig. 2 Mean changes in serum
calcium and intact PTH after
injection of 56.5 μg. teriparatide
Time courses of corrected serum
calcium (a) and intact PTH (c)
over 24 h at 0 weeks (black
circle), 4 weeks (white circle),
12 weeks (black triangle), and
24weeks (white triangle), and the
changes in the baseline levels of
corrected serum calcium (b) and
intact PTH (d) over 24 weeks.
Data are plotted as means (±SE)
*p <0.05 **p <0.01 versus 0 h or




















































Fig. 3 Mean percent changes
from 0 to 24 h for serum
osteocalcin (a), serum P1NP (b),
urinary NTX (c), and urinary
DPD (d) at 0 weeks (black
circle), 4 weeks (white circle),
12 weeks (black triangle), and
24 weeks (white triangle). Data
are plotted as means (±SE)
*p <0.05 **p <0.01 versus 0 h
with paired t test
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then decreased to the baseline level at 12 weeks (Fig. 4b). The
urinary NTX decreased significantly by 14.8% at 4 weeks and
subsequently returned to the baseline level (Fig. 4c). The
urinary DPD decreased by 17.8 % at 4 weeks and then
maintained this lower level (Fig. 4d).
Lumbar bone mineral density
The percent change in lumbar BMD increased 2.6 % from
baseline at 24 weeks.
Safety
No serious AEs were observed in this study. AEs occurred in
21 (75 %) subjects. The most frequent AEs were gastrointesti-
nal disorders (14 cases, 50.0 %), and second were skin and
subcutaneous tissue disorders and laboratory test abnormalities
(9 cases, 32.1 %). Hypercalcemia was not observed.
Discussion
This study aimed to clarify the PK, calcium metabolism, and
profile of bone turnover markers (response at 24 h after
injection and changes from baseline levels during 24 weeks)
with once-weekly injections of 56.5 μg teriparatide for
24 weeks. We previously reported on the response for up to
14 days after a single injection of 56.5 μg teriparatide in
healthy postmenopausal women [7], but whether this response
was sustained for the long-term in women with osteoporosis
was unknown.
At data collection during the 24 week observation period,
the changes in PK, calcium metabolism, and bone turnover
markers at 24 h after injection repeatedly showed the same
direction and level of response. It has been reported that, with
PTH administration, PTH/PTHrP receptors are down-regulated,
the receptor number decreases [8–10], and the receptor decrease
is also regulated at the gene expression level [11, 12]. However,
based on the results of the responses in the present study, even if
PTH/PTHrP receptors are transiently down-regulated by PTH
administration, the response was repeatedly sustained with
once-weekly injections of 56.5 μg teriparatide. This is the first
evidence in humans that the response at 24 h after injection of
teriparatide is repeated without attenuation during weekly ad-
ministration. The transient decrease followed by an increase in
bone formation markers and the transient increase followed by a
decrease in bone resorption markers at 24 h after injection of
56.5 μg teriparatide were repeated each time at the same levels
for up to 24 weeks.
PTH is reported to increase RANKL expression on osteo-
blast lineage cells and to trigger osteoclast differentiation and
activation. Ma et al. reported that, 1 h after PTH administra-
tion in mice, RANKL increased and OPG decreased at the
mRNA level, and after 3 h, they returned to baseline levels
[13]. This response after teriparatide injection, in which bone










Fig. 4 Mean percent changes in
0 h values from 0 to 24 weeks for
serum osteocalcin (a), serum
P1NP (b), urinary NTX (c), and
urinary DPD (d). Data are plotted
as means (±SE) *p <0.05
**p <0.01 versus 0 week with
paired t test
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levels after 24 h, was also confirmed in humans in the
present study.
Meanwhile, PTH in vitro has been reported to inhibit bone
formation, such as collagen synthesis [14], osteocalcin pro-
duction [15], and calcified bone-like nodule formation in
primary osteoblast cultures [16]. However, Bellows and our
group found that when PTH is removed from culture, the
osteoblast function that was inhibited was restored [15, 16].
In addition, PTH stimulates the proliferation and differentia-
tion of osteoprogenitor cells and pre-osteoblasts [15, 17],
inhibits apoptosis [18, 19], and acts to gradually increase the
osteoblast number.
Based on these findings, the 24 h responses in osteocalcin
and P1NP with injection of 56.5 μg teriparatide are explained
by inhibition of bone formation while teriparatide is present in
the blood and a subsequent return in osteoblast function with
elimination of teriparatide from the blood.
As a change from baseline levels at 24 weeks with once-
weekly injection of 56.5 μg teriparatide, a significant decrease
in intact PTHwas observed.We previously reported that intact
PTH was decreased even after 7 days with a single-dose
injection of 56.5 μg teriparatide [7]. The significant decrease
in baseline intact PTH after 12 and 24 weeks with repeated
administration in the present study is probably due to these
accumulated decreases at 7 days after teriparatide injection.
Moreover, the significant decreases after 4 and 24 weeks in
corrected serum Ca are similar to the results with long-term
administration of teriparatide by Fujita et al. [20] and our
group [4]. Changes in baseline levels of bone turnover
markers with once-weekly injection of 56.5 μg teriparatide
included increases in bone formation markers (serum
osteocalcin and P1NP) and decreases in bone resorption
markers (urinary NTX and DPD), particularly at week 4.
These baseline changes can be explained from the results of
single-dose injection of 56.5 μg teriparatide. On day 7 after
injection of 56.5 μg teriparatide, osteocalcin and P1NP in-
creased by 5 and 10 %, respectively, and NTX decreased by
10 % [7]. With repeated administration of teriparatide once-
weekly, the increases in bone formation markers and
decreases in bone resorption markers with each previous
injection accumulated. As a result, a significant change in
bone turnover markers was observed after 4 weeks in the
present study.
Moreover, the direction and level of changes in these bone
turnover markers were similar to previously reported results
with once-weekly administration of teriparatide. Fujita et al.
[20] reported that serum bone-type alkaline phosphatase
(serum BAP) increased and peaked at 4 weeks, but it de-
creased to baseline levels by 24 weeks, and urinary DPD
continued to decrease. Similar patterns of changes in bone
turnover markers were also observed in our previous trial [4].
In the present study as well, serum P1NP increased and
peaked at 4 weeks, but subsequently decreased, and urinary
DPD and urinary NTX remained the same or tended to de-
crease over the 24-week period. Thus, the changes in bone
turnover markers with once-weekly teriparatide injection were
reproduced in each report, and the level of increase in bone
formation markers in each was about 20 %. Furthermore, with
weekly teriparatide, serum osteocalcin increased significantly
after 24 weeks, but serum P1NP did not increase significantly.
Osteocalcin is produced by mature osteoblasts, but P1NP,
a collagen synthesis marker, is produced by premature
osteoblasts [21]. Therefore, the changes in serum P1NP
and serum osteocalcin with once-weekly injection of
teriparatide may indicate early stimulation of collagen
production, followed later by long-term stimulation of
collagenous matrix mineralization.
The long-term changes in bone turnover markers with daily
teriparatide administration have been fully reported. Daily
teriparatide markedly and quickly increased a bone formation
marker by 105 % after 1 month and 218 % after 6 months, and
a bone resorption marker increased by 58 % after 6 months
[22]. Serum P1NP has been established as the most specific
marker for PTH action at the osteoblastic level. In addition, a
clinical study of daily teriparatide reported that early changes
in serum P1NP can predict future increases in BMD [22] and
bone architecture [23]. The time interval and the differences in
the levels of the increases in bone formation markers and bone
resorption markers are called the “anabolic window” [24, 25].
However, the direction and level of changes in bone turn-
over markers in the present study differed from those with
daily teriparatide administration. Namely, with daily adminis-
tration, bone formation markers increased greatly (serum
PINP 218 %), and then bone resorption markers increased
(urinary NTX 58 %) [22]. In contrast, with once-weekly
injection of teriparatide, bone formation markers increased
and bone resorption markers decreased, although these
changes were small. This difference may be due to the timing
of administration (once-weekly vs. daily) and the doses of
teriparatide (56.5 vs. 20 μg). Once-weekly teriparatide treat-
ment may provide a beneficial window based on the differ-
ence between the small increase in bone formation and the
small decrease in bone resorption. Nevertheless, the effects on
fracture risk reduction were similar with the once-weekly and
daily regimens (relative risk reduction in vertebral fractures:
once-weekly teriparatide 80 % [4], daily teriparatide 65 %
[1]), the anabolic window proposed with daily teriparatide
alone may not explain the effects of weekly teriparatide on
reducing fracture risk. Therefore, explanatory factors for frac-
ture reduction other than the amount of change in bone turn-
over markers may also exist. The small increase in bone
formation and decrease in bone resorption with once-weekly
injection of teriparatide may affect the balance and regulation
of bone metabolism. With once-weekly teriparatide in ovari-
ectomized monkeys, Saito et al. explained the effects on
increasing bone strength as an improvement in bone structure
1178 Osteoporos Int (2014) 25:1173–1180
and bone quality [26]. In addition, increased lumbar spine
BMD with daily teriparatide injection accounts for 30–41 %
of vertebral fracture reduction [27], which is higher than that
with antiresorptive agents [28–30]. Therefore, an increase in
lumbar spine BMD with once-weekly teriparatide injection
may contribute to some extent to vertebral fracture reduction.
In fact, Fujita reported that incident vertebral fractures were
observed in the low- or middle-dose weekly teriparatide
group, but a greater increase in vertebral BMD, and no inci-
dent vertebral fractures were observed in the high-dose
(56.5 μg as in the present study) group [20]. Moreover, the
contribution of the change in vertebral BMD to incident
vertebral fracture with weekly teriparatide treatment in our
previous study [4] was higher (unpublished data) than that
with daily teriparatide treatment [27]. Namely, with once-
weekly teriparatide, bone density increases, collagen enzymat-
ic cross-links increase, and non-enzymatic cross-links decrease.
This results in a highly effective increase in bone strength.
Therefore, the marked fracture prevention effects with once-
weekly administration may at least be partially explained by the
difference in stimulation of bone formation and inhibition of
bone resorption as well as improvement in bone quality.
Moreover, although non-vertebral fragility fracture risk
reduction did not differ significantly with once-weekly
teriparatide injection because of the small sample size, there
tended to be a reduced risk (relative risk, 0.67; 95 % CI, 0.24–
1.84; p =0.43) [4]. Increased femoral BMD explained 87% of
the reduction in non-vertebral fracture risk for denosumab
[31] and 61 % of the reduction for zoledronic acid [32]. This
was reported to be relatively high compared to the vertebral
fracture risk reduction. Once-weekly teriparatide injection may
also reduce non-vertebral fracture risk, mainly by increasing
total hip BMD [4].
The present study did have some limitations. First, only a
single-dose regimen (once-weekly 56.5 μg teriparatide) was
used without a control group. However, regarding compari-
sons with other administration regimens, a full comparison
with the daily administration regimen was performed. Second,
the treatment evaluation period was 24 weeks (one third of the
full treatment regimen). However, the repeated responses
were sustained for at least 24 weeks, and no decreases in the
response levels were observed. In addition, the changes from
baseline levels of the bone turnover markers seen in this study
were similar to the results of the TOWER trial with a 72-week
treatment period. Thus, the responses may be sustained for up
to 72 weeks.
Conclusions
In conclusion, the present study evaluated the profile of bone
turnover markers with once-weekly injection of 56.5 μg
teriparatide for 24 weeks. Changes in PK, calcium metabolism,
and bone turnover markers at 24 h after teriparatide injection
continued in the same direction and at the same level
for 24 weeks. No loss of responsiveness was observed.
After 24 weeks, the bone formation marker serum
osteocalcin increased significantly, but serum P1NP did not
increase significantly. Bone resorption markers decreased or
remained the same.
Disclosure statement Asahi Kasei Pharma Corporation provided
funding and supplied the test drugs for this study.
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